PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Triebelhorn, J.* ; Schneider, J.* ; Spinner, C.D.* ; Iakoubov, R.* ; Voit, F.* ; Wagner, L.* ; Erber, J.* ; Rothe, K.* ; Berthele, A.* ; Pernpeintner, V.* ; Strauß, E.M.* ; Renders, L.* ; Willmann, A. ; Minic, M. ; Vogel, E. ; Christa, C. ; Hoffmann, D. ; Protzer, U. ; Jeske, S.

Clinical and immunological outcomes of SARS-CoV-2-infected vaccine responders, vaccine non-responders, and unvaccinated patients evaluated for neutralizing monoclonal antibody treatment at a single German tertiary care center: A retrospective cohort study with prospective follow-up.

Infection, DOI: 10.1007/s15010-023-02171-z (2024)
Verlagsversion DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
PURPOSE: This study assessed the clinical and immunological outcomes of SARS-CoV-2-infected patients with risk factors for severe disease depending on their immunological status. METHODS: In this retrospective study with single follow-up visit, clinical outcome and humoral immunity was monitored in SARS-CoV-2 infected patients at risk. The results were compared based on the patients' initial immunological status: unvaccinated (UV), patients who did not develop neutralizing antibodies after vaccination (vaccine non-responders, VNR), and patients who expressed neutralizing antibodies after vaccination (vaccine responders, VR). Patients who lacked neutralizing antibodies (VNR and UV) were treated with nMABs. RESULTS: In total, 113 patients at risk of severe COVID-19 consented to participate in the study. VR and UV were not admitted to the hospital. During the observation period, UVs had the highest rate of SARS-CoV-2 re-infections. Three of 41 VNRs (7.3%) were hospitalized due to severe COVID-19, with two of them having undergone iatrogenic B-cell depletion. The humoral immune response after infection was significantly lower in the VNR group than in the VR group in terms of anti-N, anti-receptor-binding domain (RBD), anti-S antibody titers, and anti-S antibody avidity. In a sub-analysis of VNR, B cell-deficient non-responders had significantly lower levels of anti-N antibodies and anti-S avidity after infection than other VNRs. CONCLUSION: VNR, particularly B-cell-depleted VNR, remained at risk of hospitalization due to COVID-19. In the VR group, however, no clinical complications or severe disease were observed, despite not receiving nMAbs. Tailoring the administration of nMABs according to patient vaccination and immunological status may be advisable.
Impact Factor
Scopus SNIP
Altmetric
5.400
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter B-cell Depletion ; Covid-19 ; Immunosuppression ; Monoclonal Antibodies ; Sars-cov-2 ; Nmabs
Sprache englisch
Veröffentlichungsjahr 2024
HGF-Berichtsjahr 2024
ISSN (print) / ISBN 0300-8126
e-ISSN 1439-0973
Zeitschrift Infection - A Journal of Infectious Disease
Verlag Urban & Vogel
Verlagsort Tiergartenstrasse 17, D-69121 Heidelberg, Germany
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Virology (VIRO)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-502700-003
G-502799-701
Förderungen Technische Universitt Mnchen (1025)
DOI 10.1007/s15010-023-02171-z
WOS ID 001154256700002
Scopus ID 85184225130
PubMed ID 38305828
Erfassungsdatum 2024-04-17
[➜Korrektur melden]